Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol greater than or equal to 100 mg/dL (greater than or equal to 2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Sanofi
- 05 Sep 2018 Results of pooled data from 14 trials, were published in the Diabetic Medicine.
- 07 Feb 2017 Pooled analysis (n=5234) of 14 trials assessing safety of very low low-density lipoprotein cholesterol levels with alirocumab, published in the Journal of the American College of Cardiology
- 06 Jan 2017 Results of a pooled target mediated drug disposition population pharmacokinetics analysis of Alirocumab from this and 12 other studies (n=2870), published in the Clinical Pharmacokinetics.